Developer docs
API playgroundTry for free, no card

Search company profiles

Numaferm

Full company profile

uuid0004ell

Namestring
Numaferm
Legal namestring
Numaferm GmbH
Websiteurl
numaferm.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Numaferm GmbH is a German biotech company founded in 2017 as a spin-off from Heinrich Heine University Düsseldorf that operates an integrated discovery-to-commercial production platform for peptides, pepteins (41-100 amino acids), and proteins using engineered E. coli microorganisms. The platform comprises Numascreen (phage display lead discovery with libraries exceeding 1 billion candidates), Numatech (high-titer expression platform incorporating Numaswitch, which uses bivalent Switchtags and inclusion bodies to achieve up to 100% refolding efficiencies, and Numasec, a secretion system delivering titers above 30 g/L with >95% purity), and Numacut TEV Protease (an AI- and directed-evolution-engineered enzyme for traceless protein cleavage). The company positions the bio-based process as delivering >90% cost-of-goods reduction and comparable carbon-footprint reduction versus chemical peptide synthesis, with 6-9 month timelines from gene to GMP drug substance.

The company generates revenue through three streams: (1) contract research services spanning lead discovery, cell line and process development, optimization and scale-up, and GMP material supply; (2) product sales, principally the Numacut TEV Protease enzyme sold via products.numaferm.com; and (3) technology licensing, exemplified by the 2023 Zoetis agreement for veterinary therapeutics. Go-to-market is sales-led direct B2B targeting pharmaceutical and life sciences buyers, supplemented by industry conference participation (BIO International, PEGS Boston, German Peptide Symposium, Swiss Biotech Day) and an established CMO partner network (Bachem, Polypeptide, Corden Pharma, Evonik, Northway Biotech, Fraunhofer) for commercial/GMP production. Pricing is quote-based and not publicly disclosed. The company is ISO 9001:2015 certified, operates a 500 m² facility in Düsseldorf, and employs approximately 30 staff including 15+ PhD scientists.

Numaferm serves customers across human pharmaceuticals (Eli Lilly teriparatide biosimilar process development), animal health (Zoetis licensing), agriculture (RWTH Aachen co-developed peptide pesticide), and aquaculture (Tunatech GmbH antimicrobial peptides for fish). Backers include Evonik Ventures, High-Tech Gründerfonds (HTGF), the European Investment Fund, and grant funding from BMBF. The company has received multiple awards including the EuropaBio Most Innovative Biotech SME Award and the Next Economy Award (2018) for sustainability.

Short descriptiontext

Numaferm GmbH is a Düsseldorf biotech founded in 2017 that operates an integrated discovery-to-GMP platform for peptides, pepteins, and proteins using proprietary engineered E. coli technology, serving pharmaceutical, animal health, agriculture, and aquaculture customers through contract services, licensing, and enzyme products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDüsseldorf, Germany
HQ citystring
Düsseldorf
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant peptide production, contract biopharmaceutical services, peptide expression technology, phage display screening, bioprocess development services
Industry1 code
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Peptide Bioprocessing Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services
TypeProfessional Services
Description

End-to-end service offerings from lead discovery (Numascreen phage display), cell line and process development (Numatech), through to commercial and GMP supply. Services include lead optimization, analytics implementation, optimization and upscaling, and material supply for GxP studies.

numaferm.com
2Product Sales
TypeOne Time License
Description

Sale of Numacut TEV Protease, a proprietary enzyme product sold for research and bioprocessing applications. Product offered via products.numaferm.com e-commerce platform.

numaferm.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies (Numaswitch, Numatech) to partners for development and production of therapeutic molecules, as exemplified by the Zoetis licensing agreement.

numaferm.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Numaswitch™
Description

Biochemical production platform for peptides, pepteins, and proteins using Switchtags and inclusion body-based production processes with up to 100% refolding efficiency.

numaferm.com
+5 more records
Core offering1 text field

Numaferm provides end-to-end contract research, bioprocess development, and manufacturing services for peptides, pepteins (41-100 aa), and proteins using proprietary E. coli-based expression platforms (Numatech, Numaswitch, Numasec) and phage display lead discovery (Numascreen). The company also sells its AI-evolved Numacut TEV Protease enzyme directly through an e-commerce store and licenses its technology platform to partners such as Zoetis for veterinary therapeutics development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Cost-of-goods reduced by more than 90% compared to chemical synthesis
+6 more records
Product overview1 text field

Numaferm is a German biotech company offering an integrated platform for peptide, peptein, and protein discovery, optimization, and production. The core offerings include: Numascreen (phage display lead discovery), Numatech (high-expression production platform containing Numaswitch and Numasec sub-technologies), and Numacut TEV Protease (enzyme for traceless protein cleavage). The Numatech platform addresses the full development pathway from discovery to commercial GMP supply through a partner network of CMOs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-07-06
Description

Licensing agreement for development and production of defined veterinary therapeutics using Numaferm's peptein technologies. Zoetis, the global leading animal health company, gains access to Numaferm's proprietary expression platform for therapeutic protein and peptide development, enhancing their internal capabilities in this field.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

Preferred partnership for sustainable peptide manufacturing innovations announced May 2023. Collaboration drives sustainable peptide manufacturing innovations combining PolyPeptide's CMO capabilities with Numaferm's production platform technologies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint development of bifunctional adhesive-antimicrobial peptide for agricultural pesticide applications. Project developing eco-friendly pesticides that are rain-resistant, safe, and do not pollute soil or food.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cooperation for development of various antimicrobial peptides (β-defensines, cathelicidins, hepcidines, histone-derivatives and piscidines) for aquaculture fish treatment applications.

5CMO Partner Network
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Established partner network of well-known CMO companies including Bachem, Polypeptide, Corden Pharma, Corden Biochem, Evonik, Northway Biotech, Richter Helms, and Fraunhofer for commercial and GMP production. The release of commercial/GMP supply takes as little as 6-9 months.

numaferm.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in peptide and oligonucleotide CDMO services. Directly comparable as both a peptide manufacturing partner and a potential competitor to Numaferm's bio-based production approach, with overlapping customer base in pharma and biotech.

TypeDirect peer
Description

Specialty CDMO for peptides and oligonucleotides. Partner of Numaferm (preferred partnership, May 2023) and a direct competitor serving the same pharma customers seeking sustainable peptide manufacturing solutions.

TypeDirect peer
Description

CDMOs across peptides, lipids, carbohydrates, and injectables. Comparable as both a partner and competitor in the peptide manufacturing space that Numaferm targets.

TypeBroad incumbent
Description

Specialty chemicals incumbent and Numaferm investor (Evonik Ventures). Operates a large-scale CDMO business with peptide-related capabilities and could integrate or compete with Numaferm's bio-based platform.

TypeEmerging player
Description

US-based peptide biotech focused on metabolic diseases using proprietary BioPure technology. Comparable as an emerging biotech commercializing novel peptide production methods and developing peptide therapeutics.

6PeptiDream
TypeEmerging player
Description

Japanese biotech with a proprietary Peptide Discovery Platform System (PDPS) for non-standard peptide therapeutics. Comparable as an emerging player with a peptide discovery and development platform targeting similar therapeutic customers.

TypeBroad incumbent
Description

Global CDMO leader with capabilities across biologics, peptides, and small molecules. Comparable as a broad incumbent that competes for outsourced peptide and biologics manufacturing contracts.

TypeBroad incumbent
Description

Life sciences tools and reagents provider with protein/peptide reagent products. Comparable as a broader incumbent selling into the same research and bioprocessing customer base, and a potential alternative source of high-quality recombinant proteins.

TypeEmerging player
Description

Clinical-stage peptide therapeutics company developing novel oral and injectable peptides. Comparable as an emerging player commercializing peptide-based therapeutics, illustrating the downstream application potential for Numaferm's production platform.

TypeRegional player
Description

European-based CDMO offering microbial and mammalian process development and GMP manufacturing. Comparable as a regional manufacturing partner/competitor within Numaferm's partner network for commercial/GMP supply.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Numaferm

Peptide Bioprocessing Servicesnumaferm.com

Numaferm GmbH is a Düsseldorf biotech founded in 2017 that operates an integrated discovery-to-GMP platform for peptides, pepteins, and proteins using proprietary engineered E. coli technology, serving pharmaceutical, animal health, agriculture, and aquaculture customers through contract services, licensing, and enzyme products.

What Numaferm does

Numaferm GmbH is a German biotech company founded in 2017 as a spin-off from Heinrich Heine University Düsseldorf that operates an integrated discovery-to-commercial production platform for peptides, pepteins (41-100 amino acids), and proteins using engineered E. coli microorganisms. The platform comprises Numascreen (phage display lead discovery with libraries exceeding 1 billion candidates), Numatech (high-titer expression platform incorporating Numaswitch, which uses bivalent Switchtags and inclusion bodies to achieve up to 100% refolding efficiencies, and Numasec, a secretion system delivering titers above 30 g/L with >95% purity), and Numacut TEV Protease (an AI- and directed-evolution-engineered enzyme for traceless protein cleavage). The company positions the bio-based process as delivering >90% cost-of-goods reduction and comparable carbon-footprint reduction versus chemical peptide synthesis, with 6-9 month timelines from gene to GMP drug substance.

The company generates revenue through three streams: (1) contract research services spanning lead discovery, cell line and process development, optimization and scale-up, and GMP material supply; (2) product sales, principally the Numacut TEV Protease enzyme sold via products.numaferm.com; and (3) technology licensing, exemplified by the 2023 Zoetis agreement for veterinary therapeutics. Go-to-market is sales-led direct B2B targeting pharmaceutical and life sciences buyers, supplemented by industry conference participation (BIO International, PEGS Boston, German Peptide Symposium, Swiss Biotech Day) and an established CMO partner network (Bachem, Polypeptide, Corden Pharma, Evonik, Northway Biotech, Fraunhofer) for commercial/GMP production. Pricing is quote-based and not publicly disclosed. The company is ISO 9001:2015 certified, operates a 500 m² facility in Düsseldorf, and employs approximately 30 staff including 15+ PhD scientists.

Numaferm serves customers across human pharmaceuticals (Eli Lilly teriparatide biosimilar process development), animal health (Zoetis licensing), agriculture (RWTH Aachen co-developed peptide pesticide), and aquaculture (Tunatech GmbH antimicrobial peptides for fish). Backers include Evonik Ventures, High-Tech Gründerfonds (HTGF), the European Investment Fund, and grant funding from BMBF. The company has received multiple awards including the EuropaBio Most Innovative Biotech SME Award and the Next Economy Award (2018) for sustainability.

Numaferm firmographics

Firmographics
Name
Numaferm
Legal name
Numaferm GmbH
Website
https://numaferm.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Numaferm GmbH is a Düsseldorf biotech founded in 2017 that operates an integrated discovery-to-GMP platform for peptides, pepteins, and proteins using proprietary engineered E. coli technology, serving pharmaceutical, animal health, agriculture, and aquaculture customers through contract services, licensing, and enzyme products.
Ownership category
akta.pro rank

Numaferm industry classification

Industry
Product category
Peptide Bioprocessing Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Recombinant peptide production
  • Contract biopharmaceutical services
  • Peptide expression technology
  • Phage display screening
  • Bioprocess development services

Where Numaferm is headquartered

Location

Headquarters

HQ city
Düsseldorf
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Numaferm business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services: End-to-end service offerings from lead discovery (Numascreen phage display), cell line and process development (Numatech), through to commercial and GMP supply. Services include lead optimization, analytics implementation, optimization and upscaling, and material supply for GxP studies.
  2. Product Sales: Sale of Numacut TEV Protease, a proprietary enzyme product sold for research and bioprocessing applications. Product offered via products.numaferm.com e-commerce platform.
  3. Technology Licensing: Licensing of proprietary technologies (Numaswitch, Numatech) to partners for development and production of therapeutic molecules, as exemplified by the Zoetis licensing agreement.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Numaferm product offering

Product offering

Core offering

Numaferm provides end-to-end contract research, bioprocess development, and manufacturing services for peptides, pepteins (41-100 aa), and proteins using proprietary E. coli-based expression platforms (Numatech, Numaswitch, Numasec) and phage display lead discovery (Numascreen). The company also sells its AI-evolved Numacut TEV Protease enzyme directly through an e-commerce store and licenses its technology platform to partners such as Zoetis for veterinary therapeutics development.

Product overview

Numaferm is a German biotech company offering an integrated platform for peptide, peptein, and protein discovery, optimization, and production. The core offerings include: Numascreen (phage display lead discovery), Numatech (high-expression production platform containing Numaswitch and Numasec sub-technologies), and Numacut TEV Protease (enzyme for traceless protein cleavage). The Numatech platform addresses the full development pathway from discovery to commercial GMP supply through a partner network of CMOs.

Differentiator

Problem solved

Functional benefit

Brands

  • Numaswitch™: Biochemical production platform for peptides, pepteins, and proteins using Switchtags and inclusion body-based production processes with up to 100% refolding efficiency.
  • Numascreen™
  • Numatech™
  • Numasec™
  • Pepteins™
  • Numacut™ TEV Protease

Quantifiable outcome

  • Cost-of-goods reduced by more than 90% compared to chemical synthesis
  • +6 more outcomes

Companies that use Numaferm

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Numaferm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Numaferm partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • ZoetisflagshipOEM/ Whitelabel/ Licensing Partner · 6 July 2023Licensing agreement for development and production of defined veterinary therapeutics using Numaferm's peptein technologies. Zoetis, the global leading animal health company, gains access to Numaferm's proprietary expression platform for therapeutic protein and peptide development, enhancing their internal capabilities in this field.
  • PolyPeptide Group AGcoreStrategic or Co-development Partner · 1 May 2023Preferred partnership for sustainable peptide manufacturing innovations announced May 2023. Collaboration drives sustainable peptide manufacturing innovations combining PolyPeptide's CMO capabilities with Numaferm's production platform technologies.
  • RWTH AachenminorStrategic or Co-development PartnerJoint development of bifunctional adhesive-antimicrobial peptide for agricultural pesticide applications. Project developing eco-friendly pesticides that are rain-resistant, safe, and do not pollute soil or food.
  • Tunatech GmbHminorStrategic or Co-development PartnerCooperation for development of various antimicrobial peptides (β-defensines, cathelicidins, hepcidines, histone-derivatives and piscidines) for aquaculture fish treatment applications.
  • CMO Partner NetworkcoreChannel Partner/ Reseller/ DistributorEstablished partner network of well-known CMO companies including Bachem, Polypeptide, Corden Pharma, Corden Biochem, Evonik, Northway Biotech, Richter Helms, and Fraunhofer for commercial and GMP production. The release of commercial/GMP supply takes as little as 6-9 months.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Numaferm competitors and assessment

Company assessment

Direct peers

  • Bachem: Global leader in peptide and oligonucleotide CDMO services. Directly comparable as both a peptide manufacturing partner and a potential competitor to Numaferm's bio-based production approach, with overlapping customer base in pharma and biotech.
  • PolyPeptide Group: Specialty CDMO for peptides and oligonucleotides. Partner of Numaferm (preferred partnership, May 2023) and a direct competitor serving the same pharma customers seeking sustainable peptide manufacturing solutions.
  • CordenPharma: CDMOs across peptides, lipids, carbohydrates, and injectables. Comparable as both a partner and competitor in the peptide manufacturing space that Numaferm targets.

Broad incumbents

  • Evonik: Specialty chemicals incumbent and Numaferm investor (Evonik Ventures). Operates a large-scale CDMO business with peptide-related capabilities and could integrate or compete with Numaferm's bio-based platform.
  • Lonza: Global CDMO leader with capabilities across biologics, peptides, and small molecules. Comparable as a broad incumbent that competes for outsourced peptide and biologics manufacturing contracts.
  • Bio-Techne: Life sciences tools and reagents provider with protein/peptide reagent products. Comparable as a broader incumbent selling into the same research and bioprocessing customer base, and a potential alternative source of high-quality recombinant proteins.

Emerging players

  • AmideBio: US-based peptide biotech focused on metabolic diseases using proprietary BioPure technology. Comparable as an emerging biotech commercializing novel peptide production methods and developing peptide therapeutics.
  • PeptiDream: Japanese biotech with a proprietary Peptide Discovery Platform System (PDPS) for non-standard peptide therapeutics. Comparable as an emerging player with a peptide discovery and development platform targeting similar therapeutic customers.
  • Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company developing novel oral and injectable peptides. Comparable as an emerging player commercializing peptide-based therapeutics, illustrating the downstream application potential for Numaferm's production platform.

Regional players

  • Northway Biotech: European-based CDMO offering microbial and mammalian process development and GMP manufacturing. Comparable as a regional manufacturing partner/competitor within Numaferm's partner network for commercial/GMP supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Numaferm social profiles

Digital presence

Numaferm compliance and trust

Trust signal

Compliance2 records

Numaferm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Numaferm leadership team

Management profile

Number of profiles

Profiles4 records

Numaferm funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Numaferm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Numaferm

What does Numaferm do?

Numaferm provides end-to-end contract research, bioprocess development, and manufacturing services for peptides, pepteins (41-100 aa), and proteins using proprietary E. coli-based expression platforms (Numatech, Numaswitch, Numasec) and phage display lead discovery (Numascreen). The company also sells its AI-evolved Numacut TEV Protease enzyme directly through an e-commerce store and licenses its technology platform to partners such as Zoetis for veterinary therapeutics development.

Is Numaferm a public or private company?

Numaferm is a private company. It is classified as venture growth investor backed and is currently operating.

When was Numaferm founded?

Numaferm was founded in 2017. It employs 11 to 50 people.

Where is Numaferm based?

Numaferm is headquartered in Düsseldorf, Germany, in the Europe region.

How does Numaferm make money?

Three revenue lines are on record. Contract Research Services are the primary driver. The others are product Sales and technology Licensing.

Who are Numaferm's main competitors?

Direct peers on record are Bachem, PolyPeptide Group and CordenPharma. Broad incumbents are Evonik, Lonza and Bio-Techne. Emerging players are AmideBio, PeptiDream and Crinetics Pharmaceuticals. Northway Biotech is listed as a regional player.

Does Numaferm have an API?

No public API is recorded for Numaferm.

What industry is Numaferm in?

Numaferm's product category is Peptide Bioprocessing Services. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comOutlook on the Peptide and Oligonucleotide CDMO Market: Major Segments, Strategic Developments, and Leading CompaniesThe peptide and oligonucleotide CDMO market is projected to reach $4.03 billion by 2030, growing at a compound annual growth rate of 10.5%, driven by advances in therapeutics, increasing rare disease and oncology investments, and rising outsourcing demand. In May 2024, EUROAPI, a France-based CDMO, acquired BianoGMP, a German CDMO specializing in oligonucleotide analytical services, strengthening EUROAPI's contract manufacturing capabilities in Frankfurt. A prior partnership in May 2023 between PolyPeptide Group AG and Numaferm GmbH also highlights strategic collaborations driving sustainable peptide manufacturing innovations.GlobeNewswirePeptide and Oligonucleotide CDMO Market Research Report 2026: $4+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe peptide and oligonucleotide CDMO market is projected to grow from $2.42 billion in 2025 to $2.7 billion in 2026, a CAGR of 11.9%, reaching $4.03 billion by 2030. Growth is driven by rising peptide therapeutics, synthetic oligonucleotide complexity, and personalized medicine, with North America leading and Asia-Pacific fastest-growing.Insightace AnalyticPeptide CDMO 2.0 Market Latest Trends Analysis Report 2025The Peptide CDMO 2.0 market is projected to grow at a 12.9% CAGR from 2025 to 2034, driven by AI-driven process optimization, machine learning integration, and continuous manufacturing technologies that reduce production costs and improve efficiency in peptide synthesis and manufacturing. Key recent developments include WuXi AppTec's launch of two new peptide manufacturing plants in China in January 2024, tripling its overall peptide synthesis capacity, and a May 2023 preferred partnership between PolyPeptide and Numaferm for sustainable peptide manufacturing. North America currently holds the largest market share due to advanced facilities, skilled workforce, and strong regulatory compliance infrastructure.Chemical & Engineering NewsPeptide makers’ new threatGerman start-up Numaferm has developed a fermentation-based biotech process for producing peptides at industrial scale, claiming to reduce manufacturing costs from the current average of $1.2 million per kilogram to between $50,000 and $100,000. The technology applies to peptides made with natural amino acids, a segment representing roughly half of the $1 billion-per-year global peptide synthesis market. Numaferm is now seeking to scale up its operations and believes the cost reduction could enable profitable use of peptides in consumer products such as cosmetics and paints.FinSMEsNumaferm Receives One-Digit Million-Euro Range Minority InvestmentNumaferm, a Düsseldorf-based peptide production company, received a minority investment in the one-digit million-euro range from backers including Evonik, High-Tech Gründerfonds, Detlev Riesner, Jürgen Schumacher, and the European Investment Fund. The funds will support technological development and bringing first products to market maturity.FinSMEsNumaferm Raises Seven-Digit FundingNumaferm, a Dusseldorf University spin-off, raised seven-digit funding from High-Tech Gründerfonds, Qiagen co-founders, and the European Investment Fund. The funds will support technological development and accelerated market entry for its peptide production technology, which has over 500 peptide-based drug candidates in the pipeline.